CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
APAM, GLP and STRA made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 19, 2024.
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, MSFT, GWW and ADBE are some stocks that hold promise.
Shares of Unilever Plc (UL) rose nearly 3% in pre-market trading Tuesday after the consumer products giant announced plans to separate Ben & Jerry's and its other ice cream brands such as Magnum into a stand-alone business, as part of a restructuring that could affect around 7,500 jobs.
National CineMedia reported fourth-quarter earnings of 24 cents a share on revenue of $90.9 million.
Unilever (NYSE: UL ) will undergo layoffs and cut about 7,500 jobs. It plans on spinning off its ice cream business in the process.
National Grid's Electricity Systems Operator (ESO) has put a £58 billion price tag on network upgrades to reach the government's 2035 decarbonisation targets. In its recommendations, the ESO touted the use of nuclear power plants Sizewell C and Hinkley Point, as well as the connection of an extra 21GW of offshore wind, plus more underground cables and pylon infrastructure.
Software stocks usually trade at steep premiums compared to the broader market. SaaS names in particular often garner nosebleed valuations exceeding 10-times forward sales (or higher), even with ho-hum growth in the low double-digits.
Pure Storage (PSTG) benefits from strong sales momentum, owing to steady demand for its product portfolio amid soft macroeconomic conditions.
Super Micro Computer (NASDAQ: SMCI ) stock is falling on Tuesday after the server and storage solutions company announced a proposed public offering for its shares. This offering has the company intending to sell 2 million shares of SMCI stock.
Atossa Therapeutics Inc (NASDAQ:ATOS), a company specializing in developing pharmaceuticals, has announced that a pre-menopausal breast cancer patient has completed a successful five-year treatment using its drug (Z)-endoxifen. The Seattle-based company reported that the patient, diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer, remains cancer-free with no significant safety or tolerability issues reported throughout the treatment period.